NOTES:

• Juvenescence is armed with $165M in funding to create “senolytic” drugs that rid the body of cells that have stopped dividing and can cause damage to other cells.

• Unity Biotechnology is developing a drug that targets senescent cells. The company, backed by Jeff Bezos, Peter Thiel, and the Longevity Fund, went public last year and is valued at $350M.

• Life Biosciences, an “age-reversal” startup, has raised more than $75Mto combat age-related decline.

• Samumed, a company that uses stem cells to regenerate hair, skin, bones, and joints, has raised $650M and is valued a $12B.

• BIOAGE has raised $33.9M from the likes of Andreessen Horowitz, Khosla Ventures, and Felicis Ventures to treat aging.

• Elysium Health ($71M funding) creates direct-to-consumer health products based on aging research.

• Calico, an Alphabet-backed anti-aging company with $2.5B in funding, has remained fairly quiet since its inception in 2013.

• ALX ONCOLOGY - Immuno-oncology drugs. (IPO 2020)

  LOYAL - Dog lifespan extension.

  DECIBEL THERAPEUTICS - Therapeutics for age-related hearing loss. (IPO 2021)

  EPIRIUM BIO - Mitochondrial biogenesis.

  FAUNA BIO - Drug discovery informed by hibernating mammals.

  GORDIAN BIOTECHNOLOGY - Multi-modal gene therapy for aging.

  METACRINE - Farnesoid drug development. (IPO 2020)

  NAVITOR PHARMACEUTICALS - mTOR modifiers.

  PRECISION BIOSCIENCES - Gene editing. (IPO 2019)

  SPRING DISCOVERY - ML aging drug discovery.

  SYSTEM1 BIOSCIENCES - Brain-organoid drug discovery.

  UNITY BIOTECHNOLOGY - Senolytics to increase healthspan. (IPO 2018)